The HIV Netherlands Australia Thailand Research Collaboration

Quick facts

Marketed products

• Grazaoprevir/Elbasavir · Virology/Hepatology
  Grazoprevir inhibits hepatitis C virus NS3/4A protease while elbasavir inhibits NS5A protein, blocking viral replication.
• Grazaoprevir/Elbasavir/RBV · Virology/Hepatology
  Grazoprevir inhibits hepatitis C virus NS3/4A protease while elbasavir inhibits NS5A protein, and ribavirin acts as a nucleoside analog to inhibit viral replication.
• Lopinavir/r plus saquinavir · Infectious Disease / Virology
  This combination of two protease inhibitors blocks HIV protease to prevent viral replication, with ritonavir boosting lopinavir levels.
• LPV/r · Infectious Disease / Virology
  LPV/r is a combination of lopinavir and ritonavir that inhibits HIV protease, preventing the maturation of HIV virions and blocking viral replication.
• LPV/r + TDF/FTC or TDF/3TC · Infectious Disease / Virology
  This combination antiretroviral regimen suppresses HIV replication by inhibiting viral protease and reverse transcriptase enzymes simultaneously.
• VZV vaccination

Phase 3 pipeline

• generic single tablet TAF/FTC/DTG

Phase 2 pipeline

• HAART containing nevirapine · Infectious Disease
  Non-nucleoside reverse transcriptase inhibitor
• Intradermal HBV 1 course
• Intramuscular HBV I course
• Nevirapine, Efavirenz
• Saquinavir, lopinavir, ritonavir
• Zidovudine, Stavudine, Didanosine, Lamivudine

Phase 1 pipeline

• GPO ritonavir versus Norvir
• ritonavir and saquinavir
• valent pneumococcal conjugated vaccine

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• The HIV Netherlands Australia Thailand Research Collaboration portfolio CI brief
• The HIV Netherlands Australia Thailand Research Collaboration pipeline updates RSS